GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University)

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameGPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsGlypican-3 modulatorsAnti-Mesothelin
TargetsGlypican-3Mesothelin
Therapy Area/IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital Of Guangzhou Medical University
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Guangzhou Medical University
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A